Sandeep De: Omicron Infection Confirmed to Raise Blood Clot Risk for 6 Months
Sandeep De, Former Senior Manager at OpenText, shared on LinkedIn about a recent article by Xintong Li et al, published in Nature, adding:
”Omicron infection raises blood clot risk for six months, three-country European study confirms
Peer-reviewed analysis of 8.4 million electronic health records across the UK, Netherlands, and Spain finds COVID-19 during the Omicron period drives venous and arterial thromboembolic events well above pre-pandemic baselines, with the steepest spike in the first 30 days.
Study design and scale:
The DARWIN EU network pulled primary care records from CPRD GOLD in the UK, IPCI in the Netherlands, and SIDIAP in Spain, comparing 7.6 million people from 2017 to 2019 against 780,000 individuals diagnosed with COVID-19 from 1 December 2021 onward, when Omicron dominated.
The European Medicines Agency funded the work.
Clotting elevation:
Standardized incidence ratios for venous thromboembolism reached 3.61 in CPRD GOLD and 4.10 in SIDIAP within 30 days of infection, roughly three to four times pre-pandemic rates.
By 180 days the ratios eased to 1.88 and 2.37 but remained statistically elevated. Pulmonary embolism, heart failure, and stroke also rose.
Among UK adults aged 55 to 64, VTE incidence hit 717 per 100,000 person-years within a month.
Vulnerable groups:
The signal ran strongest among immunocompromised people and those infected for the first time.
Prior infection appeared to offer some protection against post-COVID thrombosis, consistent with earlier work on healthcare workers showing layered immunity from infection plus vaccination.
Vaccinated individuals showed lower clotting rates than the unvaccinated.
Mechanism and continuity:
COVID-19 coagulopathy involves cytokine surges, platelet activation, endothelial dysfunction, and immune crosstalk with fibrinolytic pathways.
Earlier studies covering 48 million adults in England and Wales, plus Swedish national registries, recorded the same clotting signal during pre-Omicron waves.
The current findings extend it through the variant most often described in public messaging as mild.
The variant marketed as mild keeps producing pulmonary emboli at triple the baseline rate, six months after the test result.”
Title: Venous and arterial thromboembolic events after COVID-19 during the Omicron period in three European countries
Authors: Xintong Li, Annika M. Jödicke, Albert Prats-Uribe, Antonella Delmestri, Katia Verhamme, Mees Mosseveld, James T. Brash, Dina Vojinovic, Anna Palomar-Cros, Laura Pérez Crespo, Talita Duarte-Salles, Marek Oja, Raivo Kolde, Edward Burn, Denise Umuhire, Daniel R. Morales, Martí Català
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices